The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Usefulness of Intravitreal Bevacizumab for Retinopathy of Prematurity with Severely Dilated Tunica Vasculosa Lentis and Poor Mydriasis
Open accessAbstract
Background: Laser therapy has been the gold standard treatment for retinopathy of prematurity (ROP), while intravitreal bevacizumab (IVB) is reported to be of significant benefit for zone I ROP. A problem with laser therapy is that it is difficult to administer in ROP patients with severely dilated tunica vasculosa lentis and poor mydriasis. However, although IVB treatment has been performed in such severe ROP cases, only 1 report has discussed its usefulness. Case 1: A male infant was born with a birth weight of 382 g at 23 weeks’ gestation. As visualization was poor and laser therapy could not be performed due to dilated tunica vasculosa lentis and poor mydriasis, IVB (0.625 mg/0.025 mL) was administered to both eyes. Following treatment, the ROP gradually improved, with regression of the dilated tunica vasculosa lentis and improvement of the mydriasis in both eyes. Case 2: A male infant was born with a birth weight of 698 g at 25 weeks’ gestation. As laser therapy could not be performed due to severely dilated tunica vasculosa lentis and poor mydriasis, IVB (0.625 mg/0.025 mL) was administered to both eyes. Following treatment, the ROP gradually improved, with regression of the dilated tunica vasculosa lentis and improvement of the mydriasis in both eyes. Conclusions: IVB is potentially more useful than laser therapy for the treatment of severe ROP with dilated tunica vasculosa lentis and poor mydriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
Mintz-Hittner, H. A., Kennedy, K. A., & Chuang, A. Z. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007374 · Cited by 1,455
Hellström, A., Smith, L. E., & Dammann, O. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60178-6 · Cited by 1,304
Gilbert, C. (2008) · Early Human Development · doi:10.1016/j.earlhumdev.2007.11.009 · Cited by 790
(2007) · Pediatric Ophthalmology for Primary Care, 3rd Ed · doi:10.1542/9781581104363-ch19 · Cited by 298
Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity
Hwang, C. K., Hubbard, G. B., Hutchinson, A. K., & Lambert, S. R. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.12.017 · Cited by 223
Chavala, S. H., Farsiu, S., Maldonado, R., Wallace, D. K., Freedman, S. F., & Toth, C. A. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.003 · Cited by 172
Incidence of Retinopathy of Prematurity in the United States: 1997 through 2005
Lad, E. M., Hernandez-Boussard, T., Morton, J. M., & Moshfeghi, D. M. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.04.018 · Cited by 164
Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity
Law, J. C., Recchia, F. M., Morrison, D. G., Donahue, S. P., & Estes, R. L. (2010) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2009.10.011 · Cited by 87
Cited by
Digital technology, tele-medicine and artificial intelligence in ophthalmology: A global perspective
Li, J.-P. O., Liu, H., Ting, D. S. J., Jeon, S., Chan, R. V. P., Kim, J. E., Sim, D. A., Thomas, P. B. M., Lin, H., Chen, Y., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100900 · Cited by 626
Biology and therapeutic targeting of vascular endothelial growth factor A
Pérez-Gutiérrez, L., & Ferrara, N. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00631-w · Cited by 484
Askie, L. M., Darlow, B. A., Finer, N., Schmidt, B., Stenson, B., Tarnow-Mordi, W., Davis, P. G., Carlo, W. A., Brocklehurst, P., Davies, L. C., et al. (2018) · JAMA · doi:10.1001/jama.2018.5725 · Cited by 430
Pathophysiology and Mechanisms of Severe Retinopathy of Prematurity
Hartnett, M. E. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.050 · Cited by 351
Melanopsin and the Intrinsically Photosensitive Retinal Ganglion Cells: Biophysics to Behavior
Do, M. T. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.07.016 · Cited by 312
Metadata
- Authors
- Higashiyama, T., Muraki, S., & Ohji, M.
- Venue
- Case Reports in Ophthalmology
- Publisher
- S. Karger AG
- Published
- 2017-03-09
- Volume
- 8
- Issue
- 1
- Pages
- 173-179
- ISSN
- 1663-2699 (ISSN-L)
- OpenAlex
- W2593221228
- Cited by
- 448
- References
- 8
- FWCI
- 25.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Usefulness of Intravitreal Bevacizumab for Retinopathy of Prematurity with Severely Dilated Tunica Vasculosa Lentis and Poor Mydriasis. https://app.cochat.ai/papers/10.1159/000461575
- The paper
- Higashiyama, T., Muraki, S., & Ohji, M. (2017). Usefulness of Intravitreal Bevacizumab for Retinopathy of Prematurity with Severely Dilated Tunica Vasculosa Lentis and Poor Mydriasis. Case Reports in Ophthalmology. https://doi.org/10.1159/000461575
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.